| |
|
OMT is developing a transgenic rat for the generation of fully human monoclonal antibodies.
Monoclonal antibodies (mAbs) have been the primary focus of drug-development efforts since the early 1990s. Many pharmaceutical companies
have entered the biologics market through acquiring antibody technologies or through licensing/fee for service arrangements.
Up until now, the genetically engineered mice was the only animal-based human antibody platform available for developing new monoclonal antibodies. Pharmaceutical companies interested in licensing the transgenic mouse face:
- Limited target availability,
- Significant upfront license costs, and
- Potential milestones and royalty stacking.
|
|
|
|
